No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Clitoral Gland
|
Positive |
Positive |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland C-Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA, ADENOMA
|
Neoplastic Lesions
|
Yes
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Uterus/Cervix
|
Positive |
Positive |
(POLYP)
|
Neoplastic Lesions
|
No
|
TR-516
|
693-98-1 |
2-Methylimidazole |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/50 0/49 2/50 4/50
|
May Have Been Related
|
No
|
TR-516
|
693-98-1 |
2-Methylimidazole |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/50 1/50 3/50 3/50
|
May Have Been Related
|
No
|
TR-516
|
693-98-1 |
2-Methylimidazole |
Mice |
B6C3F1/N |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 3/50 4/49 6/49 10/50
|
Neoplastic Lesions
|
No
|
TR-516
|
693-98-1 |
2-Methylimidazole |
Mice |
B6C3F1/N |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 7/50 14/50 13/50 18/50 CARCINOMA 4/50 8/50 14/50 6/50 COMBINED 10/50 22/50 22/50 22/50
|
Neoplastic Lesions
|
Yes
|
TR-516
|
693-98-1 |
2-Methylimidazole |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/49 0/48 0/42 5/48 CARCINOMA 1/49 1/48 1/42 7/48 COMBINED 1/49 1/48 1/42 11/48
|
Neoplastic Lesions
|
Yes
|
TR-516
|
693-98-1 |
2-Methylimidazole |
Mice |
B6C3F1/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 1/50 0/50 7/50
|
Neoplastic Lesions
|
Yes
|
TR-516
|
693-98-1 |
2-Methylimidazole |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
ADENOMA OR CARCINOMA 1/48 2/46 1/43 5/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 0/51 0/53 3/51 4/55 11/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/51 0/53 1/51 3/55 1/59
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/51 3/50 2/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/52 0/50 1/51 2/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 25/50 45/51 46/53 45/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/51 2/53 4/51 3/53 3/59
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Seminal Vesicle
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/52 1/50 4/51 11/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60
|
Neoplastic Lesions
|
Yes
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52
|
Neoplastic Lesions
|
Yes
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Unspecified)
|
Clear Evidence |
Equivocal Evidence |
HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60
|
Neoplastic Lesions
|
No
|
TR-209
|
1746-01-6 |
2,3,7,8-Tetrachlorodibenzo-p-dioxin |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
CARCINOMA 1/73 2/50 2/48 6/47
|
Neoplastic Lesions
|
No
|
TR-209
|
1746-01-6 |
2,3,7,8-Tetrachlorodibenzo-p-dioxin |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
CARCINOMA 8/73 9/49 8/49 17/50
|
Neoplastic Lesions
|
No
|
TR-209
|
1746-01-6 |
2,3,7,8-Tetrachlorodibenzo-p-dioxin |
Rats |
Osborne Mendel |
Female |
Gavage |
Liver
|
Positive |
Positive |
NEOPLASTIC NODULE 5/75 1/49 3/50 12/49
|
Neoplastic Lesions
|
Yes
|
TR-209
|
1746-01-6 |
2,3,7,8-Tetrachlorodibenzo-p-dioxin |
Mice |
B6C3F1 |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA 0/69 3/50 1/47 5/46
|
Neoplastic Lesions
|
Yes
|
TR-209
|
1746-01-6 |
2,3,7,8-Tetrachlorodibenzo-p-dioxin |
Rats |
Osborne Mendel |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA 1/69 5/48 6/50 10/50
|
Neoplastic Lesions
|
No
|
TR-084
|
39156-41-7 |
2,4-Diaminoanisole sulfate |
Rats |
F344/N |
Female |
Dosed-Feed |
Clitoral Gland
|
Positive |
Positive |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-084
|
39156-41-7 |
2,4-Diaminoanisole sulfate |
Rats |
F344/N |
Male |
Dosed-Feed |
Preputial Gland
|
Positive |
Positive |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-084
|
39156-41-7 |
2,4-Diaminoanisole sulfate |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA OR BASAL CELL CARCINOMA OR SEBACEOUS ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-084
|
39156-41-7 |
2,4-Diaminoanisole sulfate |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland C-Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-084
|
39156-41-7 |
2,4-Diaminoanisole sulfate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-084
|
39156-41-7 |
2,4-Diaminoanisole sulfate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
Yes
|
TR-084
|
39156-41-7 |
2,4-Diaminoanisole sulfate |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-084
|
39156-41-7 |
2,4-Diaminoanisole sulfate |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-084
|
39156-41-7 |
2,4-Diaminoanisole sulfate |
Rats |
F344/N |
Female |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
(SEBACEOUS ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-084
|
39156-41-7 |
2,4-Diaminoanisole sulfate |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA OR SEBACEOUS ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-112
|
17026-81-2 |
3-Amino-4-ethoxyacetanilide |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-112
|
17026-81-2 |
3-Amino-4-ethoxyacetanilide |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-112
|
17026-81-2 |
3-Amino-4-ethoxyacetanilide |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-112
|
17026-81-2 |
3-Amino-4-ethoxyacetanilide |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Adrenal Gland Cortex
|
Clear Evidence |
Equivocal Evidence |
Adenoma 1/50 1/50 3/50 4/49
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
All Organs
|
Clear Evidence |
Equivocal Evidence |
Malignant Lymphoma: 2/50 5/50 8/50 7/50
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell carcinoma 0/50 1/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell carcinoma 0/50 1/50 1/49 3/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell papilloma or carcinoma 0/50 1/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Cholangiocarcinoma 1/50 1/50 1/49 3/49
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Cholangiocarcinoma 0/50 4/50 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/bronchiolar adenoma or carcinoma 0/49 2/50 1/50 4/50 alveolar/bronchiolar adenoma or carcinoma 3/49 8/50 5/50 10/50 cystic keratinizing epithelioma 0/49 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/bronchiolar adenoma 5/50 16/50 12/49 6/50 alveolar/bronchiolar adenoma or carcinoma 7/50 17/50 15/49 6/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Cystic keratinizing epithelioma 0/50 6/50 26/49 39/49
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Cystic keratinizing epithelioma 0/50 14/50 31/50 37/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Mucosa: Gingival squamous cell carcinoma 0/50 0/50 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Mucosa: Gingival squamous cell carcinoma 1/50 5/50 4/50 5/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
Fibrosarcoma 1/50 6/50 5/50 8/50 fibrosarcoma or malignant schwannoma 2/50 8/50 7/50 12/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Thoracic Cavity
|
Clear Evidence |
Equivocal Evidence |
Malignant Schwannoma: 0/50 0/50 1/50 3/50
|
May Have Been Related
|
Yes
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/50 3/50 4/50 4/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Ureter
|
Clear Evidence |
Equivocal Evidence |
Transitional epithelial carcinoma: 0/0 0/1 0/0 1/2
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Ureter
|
Clear Evidence |
Equivocal Evidence |
Transitional epithelial carcinoma: 0/43 0/45 1/47 0/50
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Urinary System
|
Clear Evidence |
Clear Evidence |
Urethra: Transitional epithelial gland carcinoma 0/50 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Urinary System
|
Clear Evidence |
Clear Evidence |
Urethra: Transitional epithelial gland carcinoma 0/50 32/50 46/49 49/50
|
Neoplastic Lesions
|
No
|
TR-186
|
101-61-1 |
4,4'-Methylenebis(N,N-dimethyl)benzenamine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-186
|
101-61-1 |
4,4'-Methylenebis(N,N-dimethyl)benzenamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-186
|
101-61-1 |
4,4'-Methylenebis(N,N-dimethyl)benzenamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-186
|
101-61-1 |
4,4'-Methylenebis(N,N-dimethyl)benzenamine |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Adrenal Gland Medulla
|
Positive |
Positive |
PHEOCHROMOCYTOMA 2/48 12/49 14/49
|
Neoplastic Lesions
|
No
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Hematopoietic System
|
Positive |
Positive |
LYMPHOMA 13/50 28/50 29/50
|
Neoplastic Lesions
|
No
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Liver
|
Positive |
Positive |
ADENOMA 3/50 9/50 12/50
|
Neoplastic Lesions
|
No
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Liver
|
Positive |
Positive |
CARCINOMA 10/49 33/50 29/50
|
Neoplastic Lesions
|
No
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Positive |
Positive |
NEOPLASTIC NODULE 1/50 12/50 25/50
|
Neoplastic Lesions
|
No
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Thyroid Gland C-Cell
|
Positive |
Positive |
ADENOMA 0/47 3/47 6/48
|
Neoplastic Lesions
|
Yes
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA 0/50 1/47 13/50
|
Neoplastic Lesions
|
Yes
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA 0/47 3/49 16/49
|
Neoplastic Lesions
|
Yes
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA 0/47 2/47 17/48
|
Neoplastic Lesions
|
Yes
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA 0/49 0/47 7/48
|
Neoplastic Lesions
|
No
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Harderian Gland
|
Positive |
Positive |
(ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Harderian Gland
|
Positive |
Positive |
(ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
Yes
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Positive |
Positive |
ADENOCARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA, CARCINOMA, ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Female |
Dosed-Feed |
Uterus/Cervix
|
Positive |
Positive |
ADENOCARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Female |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
carcinoma 1/4 6/48 12/47 3/48 8/47
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Epididymis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 2/48 2/48 1/48 5/48 8/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Epididymis or Testis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 2/48 2/48 1/48 5/48 8/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 4/46 0/46 2/48 5/45 8/42
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Male |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 0/46 2/45 2/46 6/47 6/44 squamous cell carcinoma 0/46 0/45 0/46 1/47 2/44 squamous cell papilloma or carcinoma 0/46 2/45 2/46 7/47 8/44
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 0/45 8/44 20/48 32/47 31/43
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 2/46 13/46 27/47 36/47 39/47 adenocarcinoma 0/46 0/46 0/47 1/47 1/47 adenoma or adenocarcinoma 2/46 13/46 27/47 37/47 39/47
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
malignant Schwannoma 2/48 1/48 0/48 2/48 4/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
malignant Schwannoma 1/48 2/48 3/48 4/48 6/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
adenoma 0/48 0/48 1/48 1/48 3/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 1/47 4/47 6/48 11/45 19/45
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 5/47 6/46 13/47 10/45 19/48 alveolar/bronchiolar adenoma or carcinoma 6/47 6/46 14/47 10/45 20/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
adenoacanthoma 0/47 1/46 1/48 2/45 4/42 adenocarcinoma 0/47 4/46 6/48 2/45 13/42 adenoacanthoma or adenocarcinoma 0/47 4/46 7/48 4/45 17/42
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
fibroadenoma 16/48 18/48 24/46 22/47 31/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma or carcinoma 0/48 2/48 1/48 3/48 5/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Ovary
|
Clear Evidence |
Clear Evidence |
benign granulose cell tumor 0/46 1/45 0/48 1/45 5/42
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Pancreas Islet Cell
|
Clear Evidence |
Clear Evidence |
adenoma 1/46 2/48 4/48 1/48 6/48 carcinoma 0/46 0/48 0/48 1/48 0/48 adenoma or carcinoma 1/46 2/48 4/48 2/48 6/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
fibrosarcoma, fibrous histocytoma, myxosarcoma, neurofibrosarcoma, or sarcoma 0/48 0/46 3/48 10/45 6/43 squamous cell carcinoma 0/48 0/46 0/48 0/45 2/43
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
subcutaneous tissue fibroma, fibrosarcoma or sarcoma 1/48 0/48 0/48 1/48 5/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Testis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 1/48 2/48 1/48 1/48 5/48
|
Neoplastic Lesions
|
Yes
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/48 0/48 1/48 0/48 2/47 carcinoma 0/48 0/48 1/48 3/48 2/47 adenoma or carcinoma 0/48 0/48 2/48 3/48 4/47
|
Neoplastic Lesions
|
Yes
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/47 1/48 1/47 1/48 3/48 carcinoma 1/47 2/48 3/47 6/48 6/48 l adenoma or carcinoma 1/47 3/48 4/47 6/48 9/48
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Transitional Cell
|
Some Evidence |
Some Evidence |
PAPILLOMA 0/50 0/50 2/50 0/50 1/50
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 4/50 9/50 7/50 12/49; ADENOMA OR CARCINOMA 0/50 6/50 9/50 8/50 14/49
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 1/50 3/50 9/50 5/50 3/50
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 1/50 3/50 4/50 5/50 3/50
|
May Have Been Related
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/49 28/50 27/50 40/49 OR CARCINOMA 2/49 3/50 8/50 8/49 COMBINED 6/49 30/50 30/50 41/49
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 21/50 32/50 38/50 41/49 OR CARCINOMA 8/50 13/50 17/50 21/49 OR HEPATOBLASTOMA 1/50 6/50 11/50 37/49 COMBINED 26/50 35/50 43/50 48/49
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 6/50 4/50 3/50
|
Neoplastic Lesions
|
Yes
|
TR-494
|
84-65-1 |
Anthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/45 1/48 2/48 2/48 OR CARCINOMA 0/45 0/48 0/48 2/48 COMBINED 1/45 1/48 2/48 4/48
|
May Have Been Related
|
Yes
|
TR-494
|
84-65-1 |
Anthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/50 0/50 2/49 2/46
|
May Have Been Related
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL EPITHELIAL PAPILLOMA OR CARCINOMA 0/49 0/49 0/49 1/50 2/49
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Some Evidence |
Some Evidence |
TRANSITIONAL EPITHELIAL PAPILLOMA 0/50 1/50 3/50 7/50 3/49
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
PHEOCHROMOCYTOMA 1/48 7/47 7/45 OR MALIGNANT PHEOCHROMOCYTOMA 0/48 1/47 1/45 COMBINED 1/48 8/47 8/45
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
LYMPHOMA 17/50 24/50 25/50
|
May Have Been Related
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
CARCINOMA 3/49 19/50 37/49
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
CARCINOMA 10/50 20/50 27/50
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 2/50 8/50
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/50 3/50 1/50, FIBROADENOMA 22/50 31/50 29/50, OR ADENOCARCINOMA 2/50 2/50 5/50 COMBINED 23/50 32/50 32/50
|
May Have Been Related
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Clear Evidence |
Clear Evidence |
TRICHOEPITHELIOMA 0/50 0/50 7/50; SEBACEOUS ADENOMA 0/50 0/50 5/50; SQUAMOUS CELL CARCINOMA 0/50 1/50 10/50
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Female |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
FIBROMA 0/50 15/50 10/50
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
FIBROMA 2/50 20/50 16/50
|
Neoplastic Lesions
|
Yes
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/47 0/48 4/50 OR CARCINOMA 0/47 2/48 2/50 COMBINED 0/47 2/48 6/50
|
Neoplastic Lesions
|
Yes
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/49 0/46 9/44 OR CARCINOMA 0/49 5/46 18/44
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Female |
Dosed-Feed |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 2/50 7/50
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/50 1/50 13/50
|
Neoplastic Lesions
|
No
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Rats |
F344/N |
Male |
Dosed-Feed |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
PHEOCHROMOCYTOMA 24/50 32/50 37/50 36/50
|
Neoplastic Lesions
|
No
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 0/50 0/50 6/50
|
Neoplastic Lesions
|
No
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 0/50 1/50 10/50
|
Neoplastic Lesions
|
No
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 4/50 2/50 6/50
|
May Have Been Related
|
Yes
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 0/49 1/50 5/50
|
Neoplastic Lesions
|
No
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Some Evidence |
Equivocal Evidence |
CARCINOMA 0/50 0/50 2/50 3/50
|
May Have Been Related
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
LEUKEMIA 7/50 12/50 14/50
|
May Have Been Related
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 7/50 3/49 ADENOCARCINOMA 0/50 2/50 0/49 COMBINED 0/50 9/50 3/49
|
Neoplastic Lesions
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 18/50 22/50 OR CARCINOMA 3/50 4/50 9/50 COMBINED 3/50 22/50 28/50
|
Neoplastic Lesions
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 11/50 20/50 29/50 OR CARCINOMA 11/50 15/50 17/50 COMBINED 2/50 34/50 38/50
|
Neoplastic Lesions
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 4/50 7/50; CARCINOMA 0/50 1/50 1/50
|
Neoplastic Lesions
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 10/50 16/48; CARCINOMA 0/50 3/50 2/48
|
Neoplastic Lesions
|
Yes
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Mice |
B6C3F1 |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 8/50 12/49 18/49 OR CARCINOMA 0/50 0/49 2/49 COMBINED 8/50 12/49 15/49
|
Neoplastic Lesions
|
Yes
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Rats |
F344/N |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 6/50 3/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 6/50 6/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous Cell Papilloma 0/50 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 0/50 2/50 4/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 3/50 3/50 8/50 OR CARCINOMA 1/50 2/50 0/50 1/50 COMBINED 2/50 5/50 3/50 9/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 5/50 8/50 10/50 OR CARCINOMA 0/50 0/50 2/50 2/50 COMBINED 2/50 5/50 10/50 12/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 1/49 1/50 3/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/50 2/49 3/50 9/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/49 0/50 0/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/49 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 1/50 1/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 1/50 7/50 6/50 7/50 OR CARCINOMA 0/50 2/50 0/50 1/50 COMBINED 1/50 9/50 6/50 8/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 17/50 19/49 11/50 16/50 OR CARCINOMA 4/50 11/49 14/50 19/50 COMBINED 20/50 26/49 20/50 30/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Equivocal Evidence |
Alveolar/Bronchiolar Adenoma 1/49 0/50 0/50 3/50
|
May Have Been Related
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/Bronchiolar Adenoma 2/50 16/49 29/50 26/50 or Alveolar/Bronchiolar Carcinoma 2/50 14/49 16/50 28/50 Combined 4/50 28/49 34/50 42/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/Bronchiolar Adenoma 8/50 18/50 22/50 28/50 or Alveolar/Bronchiolar Carcinoma 6/50 12/50 23/50 28/50 Combined 13/50 28/50 36/50 43/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/Bronchiolar Adenoma 2/50 0/50 3/49 3/50 or Alveolar/Bronchiolar Carcinoma 0/50 2/50 1/49 4/50 Combined 2/50 2/50 4/49 6/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 3/50 4/50 7/50 12/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 24/49 32/50 36/50 36/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 4/50 8/50 3/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/49 2/50 2/50 7/50 OR SQUAMOUS CELL CARCINOMA 0/49 1/50 3/50 4/50 COMBINED 1/49 3/50 5/50 11/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/50 4/50 10/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 2/50 COMBINED 0/50 2/50 5/50 12/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 11/50 11/50 18/50
|
Neoplastic Lesions
|
Yes
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/49 1/50 0/50 3/50 OR CARCINOMA 0/49 0/50 1/50 2/50 COMBINED 1/49 1/50 1/50 5/50
|
Neoplastic Lesions
|
Yes
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 2/49 4/50 OR CARCINOMA 0/50 0/50 2/49 1/50 COMBINED 0/50 2/50 4/49 5/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
TRANSITIONAL EPITHELIUM CARCINOMA 0/49 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
TRANSITIONAL EPITHELIUM PAPILLOMA 0/50 0/50 0/50 1/49 OR CARCINOMA 0/50 0/50 1/50 0/49
|
May Have Been Related
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Unspecified)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/50 0/50 2/50 3/50 OR HEMANGIOSARCOMA 4/50 6/50 17/50 5/50 COMBINED 4/50 6/50 18/50 8/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Unspecified)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/50 1/50 2/50 2/50 OR HEMANGIOSARCOMA 3/50 13/50 22/50 19/50 COMBINED 3/50 14/50 23/50 21/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 0/50 3/50
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
renal tubule, adenoma or carcinoma (2/50, 5/50, 8/50, 7/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
adenoma (18/50, 23/50, 27/50, 29/50); adenoma or carcinoma (25/50, 26/50, 29/50, 36/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma (1/50, 26/50, 36/50, 38/50); alveolar/bronchiolar carcinoma (3/50, 16/50, 20/50, 34/50); alveolar/bronchiolar adenoma or carcinoma (4/50, 31/50, 42/50, 46/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma (13/50, 31/50, 31/50, 29/50); alveolar/bronchiolar carcinoma (9/50, 19/50, 32/50, 33/50); alveolar/bronchiolar adenoma or carcinoma (19/50, 38/50, 42/50, 43/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Male |
Inhalation |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
respiratory epithelium, adenoma (0/50, 7/50, 18/49, 10/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Female |
Inhalation |
Nasal Cavity
|
Some Evidence |
Some Evidence |
respiratory epithelium, adenoma (0/50, 5/48, 4/50, 3/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Male |
Inhalation |
Spleen
|
Clear Evidence |
Equivocal Evidence |
hemangioscaroma
|
May Have Been Related
|
No
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Male |
Inhalation |
Testis
|
Clear Evidence |
Equivocal Evidence |
interstitial cell adenoma
|
May Have Been Related
|
Yes
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Male |
Inhalation |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
adenoma
|
May Have Been Related
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 9/50 2/50 33/50; CARCINOMA 2/50 29/50 47/50
|
Neoplastic Lesions
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 11/49 16/50 9/50; CARCINOMA 13/49 19/50 45/50
|
Neoplastic Lesions
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Pituitary Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 10/47 19/49 26/49; CARCINOMA 1/47 0/49 0/49
|
Neoplastic Lesions
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Pituitary Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/44 0/42 8/41
|
Neoplastic Lesions
|
Yes
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 35/50 CARCINOMA 0/50 0/50 8/50
|
Neoplastic Lesions
|
Yes
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/49 26/50 CARCINOMA 1/50 0/49 5/50
|
Neoplastic Lesions
|
Yes
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 6/44 28/49 CARCINOMA 2/50 1/44 8/49
|
Neoplastic Lesions
|
Yes
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/49 9/46 23/50 CARCINOMA 1/49 3/46 26/50
|
Neoplastic Lesions
|
No
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Rats |
F344/N |
Male |
Gavage |
All Organs
|
Some Evidence |
Equivocal Evidence |
Mononuclear Cell Leukemia 9/50, 12/50, 22/50, 21/50
|
May Have Been Related
|
No
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Some Evidence |
Equivocal Evidence |
hepatocellular adenoma 0/50, 3/50, 3/50, 0/50
|
May Have Been Related
|
No
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Mice |
B6C3F1/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 17/50, 37/50, 41/50, 48/50; hepatocellular carcinoma 9/50, 10/50, 15/50, 44/50; hepatoblastoma 1/50, 1/50, 8/50, 11/50
|
Neoplastic Lesions
|
No
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Mice |
B6C3F1/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma 22/50, 31/50, 41/50, 47/50; hepatoblastoma 3/50, 28/50, 36/50, 38/50
|
Neoplastic Lesions
|
No
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Rats |
F344/N |
Female |
Gavage |
Nasal Cavity
|
Some Evidence |
Equivocal Evidence |
respiratory epithelium, adenoma 0/49, 0/49, 2/50, 0/46
|
May Have Been Related
|
Yes
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Mice |
B6C3F1/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/50, 0/50, 2/50, 2/50
|
Neoplastic Lesions
|
Yes
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Rats |
F344/N |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
adenoma 1/49, 0/50, 3/49, 1/49; follicular cell, carcinoma 0/49, 0/50, 1/49, 1/49
|
Neoplastic Lesions
|
Yes
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
adenoma 2/50, 1/50, 3/49, 5/45
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
All Organs
|
Clear Evidence |
Equivocal Evidence |
Mononuclear Cell Leukemia 21/48 26/48 27/48 27/47 31/48
|
May Have Been Related
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
All Organs
|
Clear Evidence |
Clear Evidence |
Mononuclear Cell Leukemia 14/48 11/48 21/48 19/48 27/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
carcinoma 4/48 6/48 7/48 11/48 14/47
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Epididymis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 0/48 1/45 3/48 10/47 17/47
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Epididymis or Testis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 0/48 1/48 3/48 10/47 17/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 1/45 1/45 1/47 5/45 9/44
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Male |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 0/47 2/45 3/48 2/45 10/41 squamous cell carcinoma 0/47 0/45 0/48 0/45 2/41 squamous cell papilloma or carcinoma 0/47 2/45 3/48 2/45 12/41
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 0/48 1/48 0/48 0/47 3/46
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 2/45 19/47 20/47 24/46 40/46
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 3/47 17/47 23/47 32/46 42/47
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
malignant schwannoma 2/48 3/48 3/48 7/47 8/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 3/46 5/48 3/47 7/47 9/44
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 0/47 7/46 7/47 13/47 17/47
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
adenoacanthoma 0/45 0/48 0/47 1/47 8/45 adenocarcinoma 1/45 1/48 2/47 9/47 11/45 adenoacanthoma or adenocarcinoma 1/45 1/48 2/47 9/47 18/45
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
fibroadenoma 16/48 26/48 35/48 33/48 36/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Tongue: squamous cell papilloma 0/48 1/48 0/48 1/48 0/48 squamous cell carcinoma 0/48 0/48 0/48 0/48 1/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Oral mucosa or tongue: squamous cell papilloma or carcinoma 1/48 2/48 2/48 2/48 7/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Oral mucosa: squamous cell papilloma 1/48 1/48 2/48 0/48 4/48 squamous cell carcinoma 0/48 0/48 0/48 1/48 2/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Oral mucosa: squamous cell papilloma 1/48 1/48 0/48 2/47 3/48 squamous cell carcinoma 1/48 0/48 1/48 1/47 0/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Tongue: squamous cell papilloma 0/48 1/48 0/48 1/47 4/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Oral mucosa or tongue: squamous cell papilloma or carcinoma 2/48 2/48 2/48 3/47 7/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Ovary
|
Clear Evidence |
Equivocal Evidence |
granulosa cell tumor – benign or malignant 0/45 0/47 0/47 3/46 3/44
|
May Have Been Related
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
fibrosarcoma 0/45 1/48 2/47 2/47 9/45 sarcoma 0/45 0/48 1/47 3/47 3/45 fibrosarcoma or sarcoma 0/45 1/48 3/47 5/47 12/45
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 0/47 1/48 2/47 1/47 8/46 squamous cell carcinoma 0/47 0/48 0/47 0/47 2/46 squamous cell papilloma or carcinoma 0/47 1/48 2/47 1/47 9/46
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Testis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 0/48 1/47 3/48 6/47 13/48
|
Neoplastic Lesions
|
Yes
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/48 3/48 3/46 1/46 5/47 follicular cell carcinoma 0/48 0/48 2/46 3/46 3/47 follicular cell adenoma or carcinoma 0/48 3/48 5/46 4/46 8/47
|
Neoplastic Lesions
|
Yes
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 2/47 1/42 3/48 3/47 8/46 follicular cell carcinoma 0/47 2/42 3/48 1/47 5/46 follicular cell adenoma or carcinoma 2/47 3/42 6/48 4/47 13/46
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Brain
|
Clear Evidence |
Clear Evidence |
GLIOMA 0/50 4/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Brain
|
Clear Evidence |
Clear Evidence |
GLIOMA 0/50 5/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Epididymis
|
Clear Evidence |
Equivocal Evidence |
SARCOMA 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Glandular Stomach
|
Clear Evidence |
Equivocal Evidence |
FIBROSARCOMA 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LEUKEMIA 13/50 14/50 20/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 3/50 8/50 7/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 3/50 34/50 39/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50
|
Neoplastic Lesions
|
Yes
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49
|
Neoplastic Lesions
|
Yes
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 1/50 1/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/50 3/50 6/50
|
Neoplastic Lesions
|
No
|
TR-271
|
2784-94-3 |
HC Blue 1 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/50 24/48 47/49
|
Neoplastic Lesions
|
No
|
TR-271
|
2784-94-3 |
HC Blue 1 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
CARCINOMA 11/50 20/50 30/50
|
Neoplastic Lesions
|
No
|
TR-271
|
2784-94-3 |
HC Blue 1 |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
NEOPLASTIC NODULE 0/49 0/50 3/50; CARCINOMA 1/49 0/50 6/50
|
Neoplastic Lesions
|
No
|
TR-271
|
2784-94-3 |
HC Blue 1 |
Rats |
F344/N |
Female |
Dosed-Feed |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 2/49 3/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 1/49 4/50 COMBINED 1/50 3/49 7/50
|
Neoplastic Lesions
|
Yes
|
TR-271
|
2784-94-3 |
HC Blue 1 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/47 0/49 5/50
|
May Have Been Related
|
No
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 1/49 2/50 5/49
|
May Have Been Related
|
No
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Some Evidence |
Some Evidence |
ADENOMA 6/50 8/40 13/50 OR CARCINOMA 0/50 0/40 1/50 COMBINED 6/50 8/40 14/50
|
Neoplastic Lesions
|
No
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Some Evidence |
Some Evidence |
LEUKEMIA 14/50 29/50 24/50
|
Neoplastic Lesions
|
No
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Rats |
F344/N |
Male |
Gavage |
Nasal Cavity
|
Some Evidence |
Equivocal Evidence |
ADENOMA 0/48 0/47 2/49
|
May Have Been Related
|
No
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Mice |
B6C3F1 |
Female |
Gavage |
Pituitary Gland
|
Some Evidence |
Some Evidence |
ADENOMA 10/47 15/45 24/46
|
Neoplastic Lesions
|
Yes
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
CARCINOMA 0/49 5/49 1/49
|
Neoplastic Lesions
|
Yes
|
TR-487
|
115-11-7 |
Isobutene |
Rats |
F344/N |
Male |
Inhalation |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
CARCINOMA 1/48 0/48 0/48 5/50
|
Neoplastic Lesions
|
No
|
TR-448
|
542-56-3 |
Isobutyl nitrite |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/46 2/45 2/46 10/46 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/46 1/45 0/46 1/46 COMBINED 0/46 3/45 2/46 11/46
|
Neoplastic Lesions
|
No
|
TR-448
|
542-56-3 |
Isobutyl nitrite |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/46 3/46 12/46 13/46 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/46 2/46 1/46 6/46 COMBINED 1/46 5/46 13/46 15/46
|
Neoplastic Lesions
|
No
|
TR-448
|
542-56-3 |
Isobutyl nitrite |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/51 14/51 7/50 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/51 2/51 2/50 2/50 COMBINED 6/51 15/51 9/50 19/50
|
Neoplastic Lesions
|
No
|
TR-448
|
542-56-3 |
Isobutyl nitrite |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 7/50 12/50 13/49 17/53 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 6/50 5/49 4/53 COMBINED 8/50 16/50 16/49 19/53
|
Neoplastic Lesions
|
Yes
|
TR-448
|
542-56-3 |
Isobutyl nitrite |
Mice |
B6C3F1 |
Male |
Inhalation |
Thyroid Gland Follicular Cell
|
Some Evidence |
Equivocal Evidence |
ADENOMA 1/50 0/50 0/50 5/53
|
May Have Been Related
|
No
|
TR-331
|
24382-04-5 |
Malonaldehyde, sodium salt |
Rats |
F344/N |
Male |
Gavage |
Pancreas Islet Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/49 9/50 1/49
|
May Have Been Related
|
Yes
|
TR-331
|
24382-04-5 |
Malonaldehyde, sodium salt |
Rats |
F344/N |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 0/50 5/50 OR CARCINOMA 0/50 1/50 2/50 COMBINED 2/50 1/50 7/50
|
Neoplastic Lesions
|
Yes
|
TR-331
|
24382-04-5 |
Malonaldehyde, sodium salt |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 3/49 9/50 OR CARCINOMA 1/50 5/49 5/50 COMBINED 4/50 8/49 13/50
|
Neoplastic Lesions
|
No
|
TR-408
|
7487-94-7 |
Mercuric chloride |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Equivocal Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/49 2/50
|
Neoplastic Lesions
|
No
|
TR-408
|
7487-94-7 |
Mercuric chloride |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/50 12/50
|
Neoplastic Lesions
|
No
|
TR-408
|
7487-94-7 |
Mercuric chloride |
Mice |
B6C3F1 |
Male |
Gavage |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 0/50 0/50 2/49 OR ADENOCARCINOMA 0/50 0/50 1/49
|
Neoplastic Lesions
|
Yes
|
TR-408
|
7487-94-7 |
Mercuric chloride |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Some Evidence |
Equivocal Evidence |
ADENOMA 1/50 4/50 0/50 OR CARCINOMA 1/50 2/50 6/50
|
May Have Been Related
|
No
|
TR-586
|
CIMSTAR3800 |
Metal Working Fluids: CIMSTAR 3800 |
Mice |
B6C3F1/N |
Female |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
alveolar/bronchiolar carcinoma 4/50 1/50 4/50 8/50 alveolar/bronchiolar adenoma or carcinoma 4/50 5/50 6/50 12/50
|
Neoplastic Lesions
|
No
|
TR-586
|
CIMSTAR3800 |
Metal Working Fluids: CIMSTAR 3800 |
Rats |
Wistar Han |
Male |
Inhalation |
Prostate Gland
|
Equivocal Evidence |
Equivocal Evidence |
adenoma 1/50 1/50 1/50 3/50 adenoma or carcinoma 1/50 1/50 2/50 3/50
|
May Have Been Related
|
No
|
TR-586
|
CIMSTAR3800 |
Metal Working Fluids: CIMSTAR 3800 |
Rats |
Wistar Han |
Female |
Inhalation |
Skin
|
Equivocal Evidence |
Equivocal Evidence |
squamous cell papilloma or keratoacanthoma 0/50 0/50 0/50 4/50
|
May Have Been Related
|
Yes
|
TR-586
|
CIMSTAR3800 |
Metal Working Fluids: CIMSTAR 3800 |
Mice |
B6C3F1/N |
Female |
Inhalation |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
carcinoma 0/50 0/48 0/50 3/50
|
Neoplastic Lesions
|
No
|
TR-586
|
CIMSTAR3800 |
Metal Working Fluids: CIMSTAR 3800 |
Rats |
Wistar Han |
Female |
Inhalation |
Uterus
|
Equivocal Evidence |
Equivocal Evidence |
adenocarcinoma or mixed malignant Mullerian tumor (original and residual longitudinal evaluation combined) 1/50 4/50 5/50 6/50
|
May Have Been Related
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 1/50, 5/50, 6/50, 7/50; squamous cell papilloma or carcinoma 1/50, 6/50, 6/50, 7/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 17/50, 19/50, 37/50, 44/50; hepatocellular carcinoma 6/50, 13/50, 18/50, 31/50; hepatoblastoma 0/50, 1/50, 0/50, 4/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma, multiple 17/50, 19/50, 27/50, 26/50; hepatocellular carcinoma 22/50, 25/50, 30/50, 36/50; hepatoblastoma 1/50, 5/50, 10/50, 8/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma 0/50, 0/50, 0/50, 4/49; hepatocellular adenoma or carcinoma 0/50, 1/50, 1/50, 7/49
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma 0/50, 0/50, 1/50, 6/50; hepatocellular adenoma or carcinoma 0/50, 0/50, 2/50, 6/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 2/50, 4/50, 8/50, 12/50; alveolar/bronchiolar adenoma or carcinoma 2/50, 5/50, 9/50, 13/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Female |
Gavage |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
transitional epithelium, adenoma 0/50, 1/49, 0/50, 2/49
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Male |
Gavage |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
transitional epithelium, adenoma 0/50, 3/49, 2/50, 11/49; transitional epithelium, adenoma or carcinoma 0/50, 3/49, 2/50, 13/49
|
Neoplastic Lesions
|
Yes
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
adenoma or carcinoma 1/50, 2/49, 2/50, 4/49
|
May Have Been Related
|
No
|
TR-149
|
105-55-5 |
N,N'-Diethylthiourea |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-149
|
105-55-5 |
N,N'-Diethylthiourea |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-149
|
105-55-5 |
N,N'-Diethylthiourea |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-149
|
105-55-5 |
N,N'-Diethylthiourea |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-089
|
134-29-2 |
o-Anisidine hydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Transitional Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-089
|
134-29-2 |
o-Anisidine hydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-089
|
134-29-2 |
o-Anisidine hydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
(TRANSITIONAL CELL PAPILLOMA, TRANSITIONAL CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-089
|
134-29-2 |
o-Anisidine hydrochloride |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
(TRANSITIONAL CELL PAPILLOMA, TRANSITIONAL CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-089
|
134-29-2 |
o-Anisidine hydrochloride |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
(TRANSITIONAL CELL PAPILLOMA, TRANSITIONAL CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-089
|
134-29-2 |
o-Anisidine hydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
(TRANSITIONAL CELL PAPILLOMA, TRANSITIONAL CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-443
|
604-75-1 |
Oxazepam |
Mice |
Swiss Webster |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
(SWISS-WEBSTER) ADENOMA 0/60 22/59 47/59; CARCINOMA 1/60 1/59 11/59; (B6C3F1) ADENOMA 25/50 35/50 35/50 36/50; CARCINOMA 9/50 5/50 49/50 44/50; HEPATOBLASTOMA 0/50 1/50 8/50 8/50
|
Neoplastic Lesions
|
No
|
TR-443
|
604-75-1 |
Oxazepam |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
(SWISS-WEBSTER) ADENOMA 0/60 22/59 47/59; CARCINOMA 1/60 1/59 11/59; (B6C3F1) ADENOMA 25/50 35/50 35/50 36/50; CARCINOMA 9/50 5/50 49/50 44/50; HEPATOBLASTOMA 0/50 1/50 8/50 8/50
|
Neoplastic Lesions
|
No
|
TR-443
|
604-75-1 |
Oxazepam |
Mice |
Swiss Webster |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
(SWISS-WEBSTER) ADENOMA 1/60 35/60 50/60; CARCINOMA 0/60 5/60 19/60; (B6C3F1) ADENOMA 17/49 18/50 34/50 32/50; CARCINOMA 9/49 5/50 45/50 50/50; HEPATOBLASTOMA 0/49 2/50 21/50 13/50
|
Neoplastic Lesions
|
No
|
TR-443
|
604-75-1 |
Oxazepam |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
(SWISS-WEBSTER) ADENOMA 1/60 35/60 50/60; CARCINOMA 0/60 5/60 19/60; (B6C3F1) ADENOMA 17/49 18/50 34/50 32/50; CARCINOMA 9/49 5/50 45/50 50/50; HEPATOBLASTOMA 0/49 2/50 21/50 13/50
|
Neoplastic Lesions
|
Yes
|
TR-443
|
604-75-1 |
Oxazepam |
Mice |
Swiss Webster |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 4/50 5/50 6/50
|
Neoplastic Lesions
|
Yes
|
TR-443
|
604-75-1 |
Oxazepam |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 4/50 5/50 6/50
|
Neoplastic Lesions
|
No
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 5/50 7/49 32/50 46/49 hepatocellular carcinoma 4/50 2/49 6/50 27/49 hepatocellular adenoma or carcinoma 8/50 8/49 33/50 47/49
|
Neoplastic Lesions
|
No
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 23/50 35/50 49/50 40/50 hepatocellular carcinoma 18/50 15/50 30/50 45/50 hepatocellular adenoma or carcinoma 31/50 40/50 49/50 47/50 hepatoblastoma 1/50 1/50 16/50 5/50 hepatocellular adenoma, hepatocellular carcinoma, or hepatoblastoma 31/50 40/50 49/50 47/50
|
Neoplastic Lesions
|
No
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Rats |
Wistar Han |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
cholangiocarcinoma 0/50 0/49 0/50 2/47 hepatocholangioma 0/50 0/49 0/50 8/47 hepatocellular adenoma 3/50 2/49 8/50 16/47 hepatocellular carcinoma 0/50 0/49 1/50 6/47 hepatocellular adenoma or carcinoma 3/50 2/49 8/50 17/47) hepatocholangioma, hepatocellular adenoma, or hepatocellular carcinoma 3/50 2/49 8/50 21/47
|
Neoplastic Lesions
|
No
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Rats |
Wistar Han |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma or carcinoma 3/49 2/50 4/50 9/50; hepatocholangioma, hepatocellular adenoma, or hepatocellular carcinoma 3/49 2/50 4/50 11/50
|
Neoplastic Lesions
|
No
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Rats |
Wistar Han |
Male |
Gavage |
Pituitary Gland
|
Clear Evidence |
Clear Evidence |
(pars distalis): adenoma 19/49 12/49 22/50 35/50
|
Neoplastic Lesions
|
Yes
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Rats |
Wistar Han |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 1/45 3/45 2/48 6/46
|
Neoplastic Lesions
|
No
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Rats |
Wistar Han |
Female |
Gavage |
Uterus
|
Clear Evidence |
Equivocal Evidence |
stromal polyp or stromal sarcoma (original and residual evaluations, combined) 4/50 12/50 12/50 9/49
|
May Have Been Related
|
No
|
TR-476
|
125-33-7 |
Primidone (primaclone) |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
(SINGLE SECTIONS) ADENOMA 2/50 1/50 1/50 1/50 OR CARCINOMA 0/50 0/50 0/50 1/50 COMBINED 2/50 1/50 1/50 2/50; (SINGLE AND STEP SECTIONS) ADENOMA 4/50 2/50 4/50 6/50 OR CARCINOMA 0/50 0/50 0/50 1/50 COMBINED 4/50 2/50 4/50 7/50
|
Neoplastic Lesions
|
No
|
TR-476
|
125-33-7 |
Primidone (primaclone) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 15/50 42/50 45/49 47/50, CARCINOMA 3/50 11/50 19/49 38/50 OR HEPATOBLASTOMA 1/50 4/50 4/49 4/50 COMBINED 16/50 42/50 46/49 50/50
|
Neoplastic Lesions
|
No
|
TR-476
|
125-33-7 |
Primidone (primaclone) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 22/50 41/50 39/50 32/50, CARCINOMA 12/50 31/50 35/50 38/50 OR HEPATOBLASTOMA 0/50 17/50 26/50 7/50 COMBINED 31/50 49/50 49/50 46/50
|
Neoplastic Lesions
|
Yes
|
TR-476
|
125-33-7 |
Primidone (primaclone) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/49 3/48 3/50 6/50
|
Neoplastic Lesions
|
No
|
TR-476
|
125-33-7 |
Primidone (primaclone) |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 1/50 1/50 6/49 3/49 OR CARCINOMA 1/50 3/50 1/49 1/49 COMBINED 2/50 4/50 7/49 4/49
|
Neoplastic Lesions
|
No
|
TR-436
|
75-65-0 |
tert-Butyl alcohol |
Rats |
F344/N |
Male |
Dosed-Water |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
(SINGLE SECTIONS) ADENOMA 1/50 3/50 4/50 2/50 OR CARCINOMA 0/50 0/50 0/50 1/50 COMBINED 1/50 3/50 4/50 3/50; (SINGLE AND STEP SECTIONS) ADENOMA 8/50 11/50 19/50 13/50 OR CARCINOMA 0/50 2/50 1/50 1/50 COMBINED 8/50 13/50 19/50 13/50
|
Neoplastic Lesions
|
No
|
TR-436
|
75-65-0 |
tert-Butyl alcohol |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 1/60 0/59 4/59 1/57 OR CARCINOMA 0/60 0/59 0/59 1/57 COMBINED 1/60 0/59 4/59 2/57
|
Neoplastic Lesions
|
Yes
|
TR-436
|
75-65-0 |
tert-Butyl alcohol |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 2/58 3/60 2/59 9/59
|
Neoplastic Lesions
|
No
|
TR-129
|
2489-77-2 |
Trimethylthiourea |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-129
|
2489-77-2 |
Trimethylthiourea |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-129
|
2489-77-2 |
Trimethylthiourea |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-129
|
2489-77-2 |
Trimethylthiourea |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 3/50 7/50 7/50 OR CARCINOMA 0/50 1/50 0/50 COMBINED 3/50 8/50 7/50
|
Neoplastic Lesions
|
No
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Rats |
F344/N |
Female |
Gavage |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 14/50 16/50 20/50
|
May Have Been Related
|
No
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 5/50 14/50 13/50
|
May Have Been Related
|
No
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 5/50
|
Neoplastic Lesions
|
No
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 5/50 24/50
|
Neoplastic Lesions
|
No
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Mice |
B6C3F1 |
Male |
Gavage |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 1/50 1/50 3/50
|
Neoplastic Lesions
|
Yes
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Rats |
F344/N |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/50 1/50 1/50 OR CARCINOMA 0/50 2/50 3/50 COMBINED 1/50 3/50 4/50
|
May Have Been Related
|
Yes
|
TR-391
|
115-96-8 |
Tris(2-Chloroethyl) Phosphate |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/50 2/48 3/50 OR CARCINOMA 0/50 0/48 2/50 COMBINED 1/50 2/48 5/50
|
May Have Been Related
|
No
|
TR-517
|
7775-09-9 |
Water disinfection byproducts (Sodium chlorate) |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-517
|
7775-09-9 |
Water disinfection byproducts (Sodium chlorate) |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Pancreas Islet Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/46 2/47 2/49 4/49
|
Neoplastic Lesions
|
Yes
|
TR-517
|
7775-09-9 |
Water disinfection byproducts (Sodium chlorate) |
Rats |
F344/N |
Female |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
ADENOMA OR CARCINOMA 1/47 0/47 1/43 4/46
|
Neoplastic Lesions
|
Yes
|
TR-517
|
7775-09-9 |
Water disinfection byproducts (Sodium chlorate) |
Rats |
F344/N |
Male |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
CARCINOMA 0/47 0/44 0/43 4/47 ADENOMA OR CARCINOMA 1/47 0/44 0/43 6/47
|
Neoplastic Lesions
|